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Abstract
Introduction
Hypertension  is  highly  prevalent  in  Florida,  but  surveillance
through the Behavioral Risk Factor Surveillance System (BRFSS)
is limited to self-reported hypertension and does not capture data
on  undiagnosed  hypertension  or  measure  blood  pressure.  We
aimed to characterize the hypertensive population in the OneFlor-
ida Clinical Research Consortium by using electronic health re-
cords and provide proof-of-concept for using routinely collected
clinical data to augment surveillance efforts.
Methods
We identified patients with hypertension, defined as having at
least 1 outpatient visit from January 2012 through June 2016 with
an ICD-9-CM or ICD-10-CM diagnosis code for hypertension, or
in the absence of a diagnosis, an elevated blood pressure (systolic
≥140 mm Hg or diastolic ≥90 mm Hg) recorded in the electronic
health record at the most recent visit. The hypertensive population
was characterized and mapped by zip code of patient residence to
county prevalence.
Results
Of 838,469 patients (27.9% prevalence) who met the criteria for
hypertension, 68% had received a diagnosis and 61% had elev-
ated blood pressure. The geographic distribution of hypertension
differed between diagnosed hypertension (highest prevalence in
northern Florida) and undiagnosed hypertension (highest preval-
ence along eastern coast, in southern Florida, and in some rural
western Panhandle counties). Uncontrolled hypertension was con-
centrated in southern Florida and the western Panhandle.
Conclusion
Our use of clinical data, representing usual care for Floridians, al-
lows for identifying cases of uncontrolled hypertension and poten-
tially undiagnosed cases, which are not captured by existing sur-
veillance methods. Large-scale pragmatic research networks, like
OneFlorida, may be increasingly important for tailoring future
health care services, trials, and public health programs.
Introduction
Hypertension is a leading modifiable risk factor for cardiovascu-
lar disease, chronic kidney disease, stroke, and death (1,2) and the
most common condition in Florida, affecting nearly half (48.7%)
of adults aged 45 to 79 (3). Reducing blood pressure mitigates the
substantial adverse sequelae of hypertension, yet nationwide, 16%
of adults with hypertension are unaware that they have it, 24% are
untreated, and only 54% achieve blood pressure control of 140/90
mm Hg (4). The risk of hypertension-associated sequelae is partic-
ularly high in Florida, a state that ranks among the worst states in
hypertension prevalence (3). Reducing Florida’s hypertension pre-
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valence to a level similar to that of the best states (approximately
41% for men and 36% or women) could prevent up to 10% of all
cardiovascular-related deaths in Florida (3).  Achieving greater
blood pressure control is considered a high priority statewide (5).
The implementation of public health programs to mitigate the bur-
den of hypertension is hampered by a lack of information about
the disease’s regional distribution, especially the distribution of
undiagnosed and uncontrolled hypertension. Most published data
on  these  measures  come  from  surveys  conducted  nationally,
which, because of their sampling design, do not allow for detailed
analysis below the state level (ie, National Health and Nutrition
Examination Survey [NHANES]) or provide data on self-reported
measures of hypertension but no clinical correlates (ie, Behavioral
Risk Factor Surveillance System [BRFSS]). Thus, a gap exists for
regional or statewide evidence, and new data sources are needed to
better surveil disease prevalence, treatment, and health inequities
at the state and local level (6).
The development of large-scale clinical research networks has cre-
ated  opportunities  for  studying  diseases  and  their  treatments
through use of “real world” electronic health record (EHR) data.
Such networks, particularly those that integrate clinical data from
routine medical care, can augment existing surveillance efforts
with more detailed, longitudinal patient-level data. We examined
data on hypertension in the OneFlorida Clinical Research Consor-
tium (hereinafter, referred to as OneFlorida), a collaborative re-
search network of health systems, providers, and insurers in Flor-
ida, the third most populous state, which has a diverse population
and is a bellwether for demographic trends. The primary objective
of this study was to characterize the hypertensive population in
OneFlorida (7). Second, we aimed to provide proof-of-concept for
use of clinical data research networks in the surveillance of com-
mon chronic diseases like hypertension.
Methods
We performed a retrospective cross-sectional study of data on
adult patients in the OneFlorida Data Trust, a component of One-
Florida (7). OneFlorida is one of 13 clinical data research net-
works in the United States funded by the Patient-Centered Out-
comes  Research  Institute  that  constitute  the  National  Patient-
Centered Clinical Research Network (PCORnet) (8). OneFlorida
is a partnership of 11 health systems and affiliated practices in
Florida,  several  statewide  insurance  programs,  and  Florida’s
Agency for Health Care Administration, which oversees Florida
Medicaid (9). These partners provide care for more than 10 mil-
lion Floridians, nearly half of all Florida residents. OneFlorida
partners contribute clinical or administrative claims data quarterly
to the OneFlorida Data Trust (10), a secure, centralized data repos-
itory maintained at the University of Florida that integrates One-
Florida’s EHR data into PCORnet’s common data model. This
study was approved by OneFlorida’s institutional review board at
the University of Florida.
Cohort development
We included adults aged 18 or older with at least 1 ambulatory
visit or other outpatient encounter from January 1, 2012, through
June 30, 2016. This period encompasses the earliest date for which
all  partners  provided  data  to  the  Data  Trust  (January  2012)
through the most recent date (June 2016) for which the Data Trust
data had been certified as research ready by the PCORnet Co-
ordinating Center at Duke University. To be certified as research
ready, data must meet predetermined thresholds for the percent-
age of fields containing valid data, the patterns of health care use
among patients, and the amount of missing data. We included only
patient visits coded as ambulatory visits or outpatient encounters.
Being designated as hypertensive was operationalized by 1) an
ICD-9-CM (International Classification of Diseases, Ninth Revi-
sion, Clinical Modification [11]) (401, 401.0, 401.1, or 401.9) or
ICD-10-CM (International Classification of Diseases, Tenth Revi-
sion,  Clinical  Modification [12])  (I10)  diagnosis  code or  2)  a
systolic blood pressure measurement of 140 mm Hg or more or
diastolic blood pressure of 90 mm Hg or more in the EHR during
the most recent ambulatory visit or outpatient encounter. Patient-
reported blood pressure measurements were not considered. We
did not include use of antihypertensive medication as a criterion
because these data were not available from all OneFlorida part-
ners. Systolic blood pressure values of less than 70 mm Hg or
greater than 250 mm Hg were considered erroneous, recoded as
missing, and excluded, as were diastolic blood pressure values of
less than 50 mm Hg or more than 150 mm Hg.
We extracted the following data from the EHR of the most recent
visit in which a patient met our criteria for hypertension: demo-
graphic characteristics (age, race, ethnicity, sex, zip code of resid-
ence), recorded blood pressure, and clinical characteristics (body
mass index [BMI] and comorbidities). If BMI was not recorded,
we calculated BMI from weight and height measurements at that
visit.  The following measurements were considered errors,  re-
coded as missing, and excluded from analysis: BMI of less than 5
or 90 or more, a height of less than 3 feet or 8 feet or more, and a
weight of 40 pounds or less or 500 pounds or more. We also as-
sessed the type of antihypertensive medications used by each pa-
tient during the 4.5-year study period.
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Analysis
We used descriptive statistics to characterize the OneFlorida hy-
pertensive  population  overall  and by age  group (18–44 years,
45–64, 65–74, and ≥75). Hypertension prevalence was defined as
the proportion of patients meeting our hypertension criteria among
all patients with at least 1 ambulatory visit or outpatient encounter
during the study period. Prevalence of uncontrolled blood pres-
sure was defined as the proportion of patients with systolic blood
pressure of 140 mm Hg or more or diastolic blood pressure of 90
mm Hg or more, or both, among all patients with hypertension
who had at least 1 valid blood pressure measurement recorded. No
weightings were applied for the overall characterization. Because
our intention was to assess the suitability of using OneFlorida data
to augment existing surveillance efforts by qualitatively assessing
the extent to which these data accord with data from previous re-
search, we opted not to conduct statistical tests for comparisons
across age groups or other subgroups.
Using zip code of patient’s residence, we aggregated counts (hy-
pertension prevalence, uncontrolled blood pressure prevalence) to
Zip Code Tabulation Areas (ZCTAs) and county equivalents. Of
983 ZCTAs in Florida that contain residential housing, 90% exist
completely within the boundary of a single county. ZCTAs that
are bisected by a county boundary comprise only 1% of Florida’s
population. We matched zip codes to counties by using the US
Census Bureau relationship files  and constructed county-level
equivalent counts of hypertension prevalence and uncontrolled
blood pressure prevalence. ZCTA counts were aggregated to cre-
ate county rates, by quintile, and mapped, by using ArcGIS (Esri)
to characterize distributions geographically.
Results
Among 3.01 million adults included in this analysis, 838,469 were
characterized as having hypertension. Of these, 570,664 (68.1%)
were based on ICD-9-CM or ICD-10-CM diagnosis and 267,805
(31.9%) were based on blood pressure measurements (n = 159,441
[19.0%]  based  on  systolic  blood  pressure  ≥140  mm  Hg;  n  =
39,133 [4.7%] based on a diastolic blood pressure ≥90 mm Hg;
and n = 69,231 [8.3%] based on systolic blood pressure ≥140 mm
Hg and diastolic blood pressure ≥90 mm Hg) (Figure 1). The over-
all prevalence of hypertension was 27.9%, and ranged from 11.1%
among those aged 18 to 44 to 48.1% among those aged 75 or older
(Table 1).
Figure 1.  Flow diagram for  OneFlorida hypertensive cohort  identification.
Abbreviations:  EHR,  electronic  health  record;  ICD-9-CM,  International
Classification of Diseases, Ninth Revision, Clinical Modification (11); ICD-10-
CM,  International  Classification  of  Diseases,  Tenth  Revision,  Clinical
Modification (12).
 
Counties with the highest prevalence of diagnosed hypertension
and the highest overall prevalence of hypertension (diagnosed and
undiagnosed)  were concentrated primarily  in  northern Florida
(Figure 2, panel A and panel B). In contrast, the highest preval-
ence of elevated blood pressure with no hypertension diagnosis
was found primarily in rural counties in southern Florida (eg, Col-
lier, Glades, Okeechobee), some urban counties along the eastern
coast (eg, Martin, Flagler, Brevard), and some parts of the west-
ernmost Panhandle (most notably, Escambia) (Figure 2, panel C).
The 6 counties with the highest prevalence of elevated blood pres-
sure were in southern Florida and included both interior agricultur-
al counties (Highlands, Okeechobee, Collier) and urban coastal re-
tirement-destination counties (St. Lucie, Indian River, Martin).
PREVENTING CHRONIC DISEASE VOLUME 15, E27
PUBLIC HEALTH RESEARCH, PRACTICE, AND POLICY         MARCH 2018
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services,
the Public Health Service, the Centers for Disease Control and Prevention, or the authors’ affiliated institutions.
www.cdc.gov/pcd/issues/2018/17_0332.htm • Centers for Disease Control and Prevention       3
Figure 2. Prevalence, by quintile, of hypertension among patients with at least
1 ambulatory visit or outpatient encounter recorded from January 1, 2012,
through June 30, 2016, in OneFlorida, a partnership of 11 health systems and
affiliated practices in Florida, by county. Panel A, prevalence of diagnosed
hypertension;  panel  B,  prevalence  of  hypertension,  both  diagnosed  and
undiagnosed;  panel  C,  prevalence  of  elevated  blood  pressure  but  no
hypertension diagnosis.
 
Among patients with hypertension, most were women (53.7%),
white (65.6%), and non-Hispanic (76.7%). Among those with data
on BMI (90.2% of hypertensive patients), 48.4% had a BMI of
30.0 or more, and 31.3% had a BMI of 25.0 to less than 30.0. The
most prevalent comorbidities were dyslipidemia (38.9%), diabetes
(24.2%), and coronary artery disease (13.3%); the prevalence of
comorbidities differed by age group (Table 1).
Blood pressure data were available for 722,623 (86.2%) hyper-
tensive patients. Mean (standard deviation [SD]) blood pressure in
the population was 139 (19) mm Hg systolic and 80 (12) mm Hg
diastolic.  Increasing  age  was  associated  with  increased  mean
systolic blood pressure and decreased mean diastolic blood pres-
sure. Overall, 61.0% had uncontrolled blood pressure. Among hy-
pertensive patients, the prevalence of blood pressure control was
lowest among those aged 18 to 44 (28% controlled) but was gener-
ally similar (~40% to 42%) across older age groups.
Collier County, in southwestern Florida, had the highest preval-
ence of uncontrolled blood pressure (85.6%), regardless of dia-
gnosis, and the coastal-retirement destination counties of Monroe,
PREVENTING CHRONIC DISEASE VOLUME 15, E27
PUBLIC HEALTH RESEARCH, PRACTICE, AND POLICY         MARCH 2018
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services,
the Public Health Service, the Centers for Disease Control and Prevention, or the authors’ affiliated institutions.
4       Centers for Disease Control and Prevention  •  www.cdc.gov/pcd/issues/2018/17_0332.htm
Indian River, St. Lucie, and Martin each had a prevalence of 78%
or more (Figure 3, panel A). Among patients with a hypertension
diagnosis, we found the highest prevalence (50.8%) in Monroe
County, followed by Dixie and Broward counties, each with a pre-
valence of 43% (Figure 3, panel B).
Figure 3. Prevalence, by quintile, of uncontrolled blood pressure (≥140/90
mm Hg)  among hypertensive  patients  with  at  least  1  ambulatory  visit  or
outpatient encounter recorded from January 1, 2012, through June 30, 2016,
in OneFlorida, a partnership of 11 health systems and affiliated practices in
Florida,  by  county.  Panel  A,  prevalence  of  uncontrolled  blood  pressure,
regardless of hypertension diagnosis; panel B, prevalence of uncontrolled
blood pressure only among those with a hypertension diagnosis.
 
Data on prescribed medications were available for 519,879 pa-
tients, or 62.0% of the overall hypertensive population. Of these,
13.2% were prescribed no medications, 27.9% were prescribed
medications other than antihypertensive medications, and 58.9%
were prescribed at least 1 antihypertensive medication. Among
those with diagnosed hypertension (Table 2), the most commonly
prescribed  medications  were  angiotensin-converting  enzyme
(ACE) inhibitors (39.6% of patients), β-blockers (34.5%), calci-
um channel  blockers  (29.7%),  and thiazide  diuretics  (29.7%).
Among those with elevated blood pressure but no hypertension
diagnosis, β-blockers (13.1%), ACE inhibitors (9.7%), and calci-
um channel blockers (9.5%) were the most commonly prescribed
antihypertensive medications (Table 3).
Discussion
Our study, to our knowledge, is the largest cross-sectional study of
Floridians with hypertension and among the first wide-scale ef-
forts to use clinical data from real-world usual care in a health sys-
tem that spans an entire state. We observed an overall hyperten-
sion prevalence of 27.9% among adult patients with at least 1 am-
bulatory visit or outpatient encounter. Of these, approximately
two-thirds had diagnosed hypertension, and the remainder had el-
evated blood pressure but no diagnosis. This overall prevalence is
lower than the 33.5% of adults in the 2015 BRFSS who reported
having ever been told they had high blood pressure (13). As we
anticipated, prevalence differed by age group, with the lowest pre-
valence among those aged 18 to 44 and a higher prevalence among
older patients. The proportion with elevated blood pressure but no
hypertension diagnosis (among the overall hypertensive cohort)
decreased from 49.6% among those aged 18 to 44 years to 27.0%
among those aged 75 or older, suggesting that older patients were
more likely to receive a diagnosis.  We also observed a higher
overall  hypertension  prevalence  among  women  (53.7%)  than
among men (46.3%); in contrast, BRFSS estimates show a higher
prevalence of hypertension among men in Florida (13). The differ-
ences between our results and those of BRFSS may reflect differ-
ences between the 2 cohorts in the distribution of older women;
hypertension prevalence and average blood pressure are higher
among men than women younger than 45, whereas the reverse is
true among those aged 65 or older (4,14–16). Alternatively, the
higher prevalence among women may reflect their more frequent
interaction with the health care system, resulting in a greater op-
portunity for diagnosing hypertension. Finally, among all patients
with hypertension in our study, 21.0% were black and 65.6% were
white. However, the black population was overrepresented in the
younger age groups and underrepresented in the older age groups.
These racial distributions are generally consistent with population
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distributions in Florida, where the black population is approxim-
ately 15% of the overall adult population but only 9% of those
aged 65 to 74 and less than 7% of those aged 75 or older (17). The
reason for this racial distribution is not clear but may relate to ra-
cial disparities in migration patterns into and out of the state. Al-
ternatively, these data may reflect the well-known disparities in
hypertension-related mortality between black and white Ameri-
cans (18).
Our data source allowed for mapping of hypertension prevalence.
We observed the highest overall hypertension prevalence in north-
ern Florida, an area that is demographically and geographically
similar  to  much  of  the  southeastern  United  States,  which  has
among the highest rates of hypertension in the nation. Not coincid-
entally, the areas in northern Florida also comprise the southern
border of the US stroke belt, which historically has had higher
levels  of  age-adjusted stroke mortality  than other  areas of  the
United States. Our results are also consistent with those of previ-
ous studies that combined NHANES and BRFSS data and showed
that the highest prevalence of hypertension in Florida is in the
northern part  of  the state  (19).  Likewise,  recent  data from the
Reasons for Geographic and Racial Differences in Stroke project
show that the highest hypertension prevalence among both blacks
and whites in Florida is in the northwestern part of the state (20).
Patients with elevated blood pressure but no hypertension diagnos-
is were concentrated in multiple areas, including rural areas of
southern Florida, eastern coastal counties, and some rural counties
of the western Panhandle. BRFSS generates county-level estim-
ates of hypertension prevalence based on patient self-report, but it
does not capture data on hypertension among those with no dia-
gnosis or knowledge of having the disease. Thus, our approach is
useful for pinpointing regions that need programs to reduce the
prevalence of uncontrolled hypertension and other chronic dis-
eases that contribute to the large and growing racial/ethnic dispar-
ities in diseases (eg, stroke [21]), and in life expectancy (22,23).
Finally, we explored data on common antihypertensive medica-
tions to better understand their real-world use among Floridians
with hypertension. Not surprisingly, the 4 most commonly used
classes of medication were ACE inhibitors, β-blockers, calcium
channel blockers, and diuretics (especially thiazides). These data
appear consistent with national estimates based on NHANES data
from 2001 to 2010 (14). Our data could be useful, for example, in
identifying and targeting disparities in medication selection or
dosing among various segments of the population.
Our study and data source have several strengths. First, we used
clinical data, rather than patient-reported data, to identify hyper-
tension cases.  Our approach allowed for  ascertaining cases of
physician-diagnosed hypertension and cases of hypertension with
no documented diagnosis. Detection of hypertension, particularly
cases for which no diagnosis is documented, may allow for more
focused interventions in the health care system, public health sec-
tor, or both, to prevent the adverse sequelae of uncontrolled blood
pressure. Second, the detailed information on patients in the One-
Florida Data Trust allowed for a more granular view of hyperten-
sion  in  Florida  than  provided  by  surveys  such  as  BRFSS and
NHANES. Our study produced data on overall hypertension pre-
valence; prevalence by age, sex, race/ethnicity, and geographic re-
gion; and detailed characterization by age group. Areas of future
study include analyzing time trends in hypertension prevalence,
blood pressure control, antihypertensive treatment, and other para-
meters related to hypertension for the overall population in Flor-
ida and subgroups. Furthermore, development and validation of
outcome measures in the PCORnet common data model will al-
low for a transition from descriptive studies of individual popula-
tions (eg, Florida) to use of inferential statistics to better under-
stand care and treatment effects across larger populations from
which these patients are sampled. Third, because these data are
collected as part of routine care, they do not require substantial
financial investment to update regularly, beyond the initial and on-
going infrastructure costs for the clinical data research network.
Although such data are not expected to supplant ongoing surveil-
lance efforts, they may be a useful and cost-effective adjunct to
identifying disparities and areas of need for public health invest-
ment.
Several limitations should also be noted. First, our data are not ne-
cessarily generalizable to the entire adult population of Florida or
adult populations in other states. Although OneFlorida partners
provide care for nearly half of all Floridians, outpatient data were
available only for approximately 25% of Floridian adults when we
conducted  this  study.  Moreover,  systematic  differences  exist
between persons who engage the health care system and those
who do not. For example, patients in the health care system are
sicker than the general population, which could prompt overestim-
ation of hypertension prevalence in the general population. Con-
versely, some adults with low socioeconomic status and who lack
medical insurance (eg, low-income, childless adults) may forgo
routine outpatient visits. Data on such patients, who are at elev-
ated risk of having both hypertension and uncontrolled blood pres-
sure (24), would not be captured in OneFlorida, thus resulting in
underestimation of prevalence. Nevertheless, to our knowledge,
OneFlorida is the largest clinical data repository for adults receiv-
ing health care in Florida. Second, we excluded potential hyper-
tension cases in which care was received only in an inpatient or
emergency department setting. Third, our definition of hyperten-
sion included a blood pressure of 140/90 mm Hg or more. This
definition is consistent with definitions in other large representat-
ive data sets (ie, NHANES); however, we cannot exclude the pos-
sibility of generating false-positive cases of hypertension by using
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this  definition,  either  because  blood  pressure  was  improperly
measured or inaccurately recorded or because of some other pa-
tient- or visit-specific factor (eg, patient sought care for pain) that
may have accounted for a lone elevated blood pressure. Thus, our
definition of hypertension, which included patients with no hyper-
tension diagnosis, may have resulted in the overestimation of un-
diagnosed hypertension. Finally, general limitations exist for us-
ing EHR data, particularly diagnostic codes, in research, because
such data are collected primarily for the purposes of billing. For
example, use of ICD codes for identifying hypertension cases have
reasonably high but imperfect sensitivity and specificity (25,26).
We analyzed data on more than 3 million patients in OneFlorida
for evidence of hypertension and found an overall prevalence of
27.9%. We further  provided proof-of-concept  for  the use of  a
large, integrated, clinical data repository in augmenting surveil-
lance of chronic diseases such as hypertension. The advantages to
our approach include the use of existing clinical data (represent-
ing usual care), which allows for identifying patients with uncon-
trolled blood pressure but no hypertension diagnosis, and the abil-
ity to parse outcomes on the basis of detailed patient-level data
such as age, race/ethnicity, and geographic location. As the nation
moves toward the goal of creating health systems in which patient
care informs evidence as much as evidence informs patient care,
pragmatic research networks, like OneFlorida, may be increas-
ingly relied on to inform future health care, support the design and
conduct of clinical trials, and enhance public health efforts.
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Tables
Table 1. Characteristics of Adults With Hypertension in the OneFlorida Data Trust, January 2012–June 2016a
Characteristic
Age Group, y
Total18–44 45–64 65–74 ≥75
Total eligible populationb 1,190,542 1,046,467 421,897 351,149 3,010,055
Met criteria for hypertension 132,459 (11.1) 350,448 (33.5) 186,737 (44.3) 168,825 (48.1) 838,469 (27.9)
≥1 ICD-9-CM or ICD-10-CM diagnosisc 66,807 (50.5) 245,451 (70.0) 135,213 (72.4) 123,193 (73.0) 570,664 (68.1)
Systolic blood pressure ≥140 mm Hgc,d 25,968 (19.6) 54,530 (15.6) 39,407 (21.1) 39,536 (23.4) 159,441 (19.0)
Diastolic blood pressure ≥90 mm Hgc,d 19,030 (14.4) 16,623 (4.7) 2,422 (1.3) 1,058 (0.6) 39,133 (4.7)
Systolic blood pressure ≥140 and diastolic blood
pressure ≥90 mm Hgc,d
20,654 (15.6) 33,844 (9.7) 9,695 (5.2) 5,038 (3.0) 69,231 (8.3)
Demographicc
Female 68,300 (51.6) 185,605 (53.0) 99,132 (53.1) 97,388 (57.7) 450,425 (53.7)
Race
  White 74,477 (56.2) 219,302 (62.6) 132,254 (70.8) 123,793 (73.3) 549,826 (65.6)
  Black 40,376 (30.5) 86,307 (24.6) 29,704 (15.9) 19,810 (11.7) 176,197 (21.0)
  Other 906 (0.7) 2,498 (0.7) 1,028 (0.6) 595 (0.4) 5,027 (0.6)
  Unknown 16,700 (12.6) 42,341 (12.1) 23,751 (12.7) 24,627 (14.6) 107,419 (12.8)
Ethnicity
  Hispanic 26,252 (19.8) 70,011 (20.0) 29,293 (15.7) 24,475 (14.5) 150,031 (17.9)
  Non-Hispanic 98,707 (74.5) 263,062 (75.1) 147,831 (79.2) 133,561 (79.1) 643,161 (76.7)
  Unknown 7,498 (5.7) 17,373 (5.0) 9,612 (5.1) 10,787 (6.4) 45,270 (5.4)
Blood pressuree 120,400 (90.9) 305,500 (87.2) 159,661 (85.5) 137,062 (81.2) 722,623 (86.2)
Systolic blood pressure, mm Hg, mean (SD) 138 (16) 138 (18) 140 (20) 141 (21) 139 (19)
Diastolic blood pressure, mm Hg, mean (SD) 86 (11) 82 (11) 77 (11) 73 (11) 80 (12)
Systolic blood pressure ≥140 and diastolic blood
pressure ≥90 mm Hgf
31,455 (26.1) 62,984 (20.6) 17,521 (11.0) 9,077 (6.6) 121,037 (16.7)
Systolic blood pressure ≥140 or diastolic blood
pressure ≥90 mm Hgf
55,534 (46.1) 117,709 (38.5) 74,340 (46.6) 72,875 (53.2) 320,458 (44.3)
Body mass index,e kg/m2 122,338 (92.4) 319,259 (91.1) 167,776 (89.8) 146,561 (86.8) 755,934 (90.2)
<25.0f 19,581 (16.0) 49,276 (15.4) 33,847 (20.2) 50,764 (34.6) 153,468 (20.3)
25.0 to <30.0f 30,162 (24.7) 94,186 (29.5) 57,568 (34.3) 54,951 (37.5) 236,867 (31.3)
≥30.0f 72,595 (59.3) 175,797 (55.1) 76,361 (45.5) 40,846 (27.9) 365,599 (48.4)
Abbreviations: ICD-9-CM, International Classification of Diseases, Ninth Revision, Clinical Modification (11); ICD-10-CM, International Classification of Diseases,
Tenth Revision, Clinical Modification (12); SD, standard deviation.
a Values are number (percentage) unless otherwise indicated.
b All patients in OneFlorida with at least 1 ambulatory care visit at which blood pressure was measured.
c Percentage in each cell was calculated as the cell number (numerator) divided by the corresponding cell number for “Met criteria for hypertension” (denominator).
d Category excludes patients with a hypertension diagnosis (ICD-9-CM or ICD-10-CM).
e Row describes number (% of all patients with hypertension) with nonmissing data for this variable.
f Percentage in each cell was calculated as the cell number (numerator) divided by the corresponding number of patients with nonmissing data (denominator) for
the variable.
(continued on next page)
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(continued)
Table 1. Characteristics of Adults With Hypertension in the OneFlorida Data Trust, January 2012–June 2016a
Characteristic
Age Group, y
Total18–44 45–64 65–74 ≥75
Comorbiditiesc
Diabetes 15,313 (11.6) 85,155 (24.3) 55,596 (29.8) 47,149 (27.9) 203,213 (24.2)
Coronary artery disease 2,267 (1.7) 33,224 (9.5) 33,610 (18.0) 42,662 (25.3) 111,763 (13.3)
Chronic kidney disease 4,626 (3.5) 20,406 (5.8) 17,791 (9.5) 26,021 (15.4) 68,844 (8.2)
Dyslipidemia 21,483 (16.2) 130,130 (37.1) 89,600 (48.0) 84,609 (50.1) 325,822 (38.9)
Peripheral arterial disease 1,014 (0.8) 10,776 (3.1) 10,797 (5.8) 13,517 (8.0) 36,104 (4.3)
Angina 1,417 (1.1) 12,780 (3.7) 8,738 (4.7) 7,735 (4.6) 30,670 (3.7)
Myocardial infarction 1,124 (0.9) 12,052 (3.4) 9,695 (5.2) 11,285 (6.7) 34,156 (4.1)
Stroke 1,239 (0.9) 8,199 (2.3) 6,057 (3.2) 8,383 (5.0) 23,878 (2.9)
Major depression 7,478 (5.7) 22,712 (6.5) 8,323 (4.5) 5,551 (3.3) 44,064 (5.3)
Minor depression 10,469 (7.9) 35,294 (10.1) 16,059 (8.6) 13,425 (8.0) 75,247 (9.0)
Dementia 71 (0.1) 1,213 (0.4) 3,123 (1.7) 15,886 (9.4) 20,293 (2.4)
Memory loss 701 (0.5) 3,511 (1.0) 3,165 (1.7) 6,099 (3.6) 13,476 (1.6)
Chronic heart failure 2,031 (1.5) 13,794 (3.9) 11,706 (6.3) 21,217 (12.6) 48,748 (5.8)
Abbreviations: ICD-9-CM, International Classification of Diseases, Ninth Revision, Clinical Modification (11); ICD-10-CM, International Classification of Diseases,
Tenth Revision, Clinical Modification (12); SD, standard deviation.
a Values are number (percentage) unless otherwise indicated.
b All patients in OneFlorida with at least 1 ambulatory care visit at which blood pressure was measured.
c Percentage in each cell was calculated as the cell number (numerator) divided by the corresponding cell number for “Met criteria for hypertension” (denominator).
d Category excludes patients with a hypertension diagnosis (ICD-9-CM or ICD-10-CM).
e Row describes number (% of all patients with hypertension) with nonmissing data for this variable.
f Percentage in each cell was calculated as the cell number (numerator) divided by the corresponding number of patients with nonmissing data (denominator) for
the variable.
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Table 2. Antihypertensive Medications Prescribed Among Patients With ICD-9-CM–Diagnosed or ICD-10-CM–Diagnosed Hypertension in OneFlorida, January
2012–June 2016a
Medication Class
Age Group, y
Total18–44 45–64 65–74 ≥75
Calcium channel blockers 10,840 (22.7) 47,288 (28.7) 24,476 (31.9) 20,863 (35.8) 103,467 (29.7)
Angiotensin-converting enzyme (ACE) inhibitors 17,244 (36.0) 71,598 (43.4) 29,560 (38.5) 19,309 (33.1) 137,711 (39.6)
Angiotensin receptor blockers (ARBs) 4,538 (9.5) 27,005 (16.4) 16,138 (21.0) 12,976 (22.2) 60,657 (17.4)
β-Blockers 11,980 (25.0) 52,366 (31.7) 29,650 (38.6) 25,986 (44.5) 119,982 (34.5)
Diuretics
Thiazides 12,970 (27.1) 53,072 (32.2) 22,928 (29.9) 14,322 (24.5) 103,292 (29.7)
Aldosterone antagonists 980 (2.0) 4,705 (2.9) 2,612 (3.4) 1,978 (3.4) 10,275 (3.0)
Other 3,324 (6.9) 18,102 (11.0) 12,053 (15.7) 12,938 (22.2) 46,417 (13.3)
Others 3,245 (6.8) 11,599 (7.0) 5,231 (6.8) 4,481 (7.7) 24,556 (7.1)
Abbreviations: ICD-9-CM, International Classification of Diseases, Ninth Revision, Clinical Modification (11); ICD-10-CM, International Classification of Diseases,
Tenth Revision, Clinical Modification (12).
a Values are number (percentage) among 347,948 patients with diagnosed hypertension for whom data on prescriptions were available.
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Table 3. Antihypertensive Medications Prescribed Among Patients With an Elevated Blood Pressure But No ICD-9-CM–Diagnosed or ICD-10-CM–Diagnosed Hyper-
tension in OneFlorida, January 2012–June 2016a
Medication Class
Age Group, y
Total18–44 45–64 65–74 ≥75
Calcium channel blockers 1,230 (2.8) 5,353 (8.0) 4,043 (12.8) 5,625 (19.0) 16,251 (9.5)
Angiotensin-converting enzyme (ACE) inhibitors 1,367 (3.1) 6,851 (10.3) 4,160 (13.2) 4,371 (14.7) 16,749 (9.7)
Angiotensin receptor blockers (ARBs) 476 (1.1) 3,935 (5.9) 3,523 (11.2) 4,661 (15.7) 12,595 (7.3)
β-Blockers 2,174 (4.9) 7,339 (11.0) 5,531 (17.5) 7,505 (25.3) 22,549 (13.1)
Diuretics
Thiazides 898 (2.0) 4,501 (6.8) 3,063 (9.7) 3,245 (10.9) 11,707 (6.8)
Aldosterone antagonists 193 (0.4) 506 (0.8) 315 (1.0) 386 (1.3) 1,400 (0.8)
Other 541 (1.2) 2,252 (3.4) 1,756 (5.6) 2,975 (10.0) 7,524 (4.4)
Others 676 (1.5) 1,371 (2.1) 838 (2.7) 1,188 (4.0) 4,073 (2.4)
Abbreviations: ICD-9-CM, International Classification of Diseases, Ninth Revision, Clinical Modification (11); ICD-10-CM, International Classification of Diseases,
Tenth Revision, Clinical Modification (12).
a Values are as number (percentage) among 171,931 undiagnosed patients with medication data.
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